Inhibition of toll-like receptor 4 with Vasoactive intestinal peptide attenuates liver ischemia-reperfusion injury

Transplantation Proceedings

Volumn 43, Issue 5, 2011, Pages 1462-1467

  Jiang, W ^a   Tang, W ^a   Geng, Q ^a   Xu, X ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEMATOXYLIN; INTERLEUKIN 6; MESSENGER RNA; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; EDEMA; IN VIVO STUDY; LIVER ISCHEMIA; MACROPHAGE; MALE; MOUSE; NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY; STAINING;

ALANINE TRANSAMINASE; ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE; DNA PRIMERS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; LIVER; MALE; MICE; MICE, INBRED C57BL; POLYMERASE CHAIN REACTION; REPERFUSION INJURY; RNA, MESSENGER; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA; VASOACTIVE INTESTINAL PEPTIDE;

EID: 79959461039     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.01.191     Document Type: Article

References (36)

1. M.L. Alegre, J. Leemans, and A. Le Moine The multiple facets of toll-like receptors in transplantation biology Transplantation 86 2008 1
2. J. Oyama, C. Blais Jr, and X. Liu Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice Circulation 109 2004 784
3. A. Shimamoto, A.J. Chong, and M. Yada Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury Circulation 114 2006 1270
4. R. Medzhitov, P. Preston-Hurlburt, and C.A. Janeway Jr A human homologue of the Drosophila Toll protein signals activation of adaptive immunity Nature 388 1997 394
5. S. Akira, S. Uematsu, and O. Takeuchi Pathogen recognition and innate immunity Cell 124 2006 783
6. Y. Zhai, B. Qiao, and X.D. Shen Evidence for the pivotal role of endogenous toll-like receptor 4 ligands in liver ischemia and reperfusion injury Transplantation 85 2008 1016
7. Y. Zhai, B. Qiao, and F. Gao Type I, but not type II, interferon is critical in liver injury induced after ischemia and reperfusion Hepatology 47 2008 199
8. H.S. Wu, J.X. Zhang, and L. Wang Toll-like receptor 4 involvement in hepatic ischemia/reperfusion injury in mice Hepatobiliary Pancreat Dis Int 3 2004 250
9. K. Takeda, and S. Akira Toll-like receptors in innate immunity Int Immunol 17 2005 1
10. J. Obhrai, and D.R. Goldstein The role of toll-like receptors in solid organ transplantation Transplantation 81 2006 497
11. A.R.M. Iwasaki Toll-like receptor control of the adaptive immune responses Nat Immunol 5 2004 98
12. N.M. Sherwood, S.L. Krueckl, and J.E. McRory The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily Endocr Rev 21 2000 619
13. M. Kojima, T. Ito, and T. Oono VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production Pancreas 30 2005 62
14. C. Abad, C. Martinez, and M.G. Juarranz Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease Gastroenterology 124 2003 961
15. M. Delgado, C. Abad, and C. Martinez Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease Nat Med 7 2001 563
16. M. Delgado, C. Martinez, and D. Pozo Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6 J Immunol 162 1999 b1200
17. F. Rosignoli, M. Torroba, and Y. Juarranz VIP and tolerance induction in autoimmunity Ann N Y Acad Sci 1070 2006 525
18. C. Martinez, C. Abad, and M. Delgado Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor Proc Natl Acad Sci U S A 99 2002 1053
19. D. Fabricius, M.S. O'Dorisio, and S. Blackwell Human plasmacytoid dendritic cell function: inhibition of IFN-alpha secretion and modulation of immune phenotype by vasoactive intestinal peptide J Immunol 177 2006 5920
20. D.A. Bechtold, T.M. Brown, and S.M. Luckman Metabolic rhythm abnormalities in mice lacking VIP-VPAC2 signaling Am J Physiol Regul Integr Comp Physiol 294 2008 R344
21. X.D. Shen, B. Ke, and Y. Zhai Stat4 and Stat6 signaling in hepatic ischemia/reperfusion injury in mice: HO-1 dependence of Stat4 disruptionmediated cytoprotection Hepatology 37 2003 296
22. R.M. Zwacka, W. Zhou, and Y. Zhang Redox gene therapy for ischemia/reperfusion injury of the liver reduces AP1 and NF-kappaB activation Nat Med 4 1998 698
23. F. Dnceli, S.O. Ieri, and F. Ercan Oxytocin alleviates hepatic ischemia-reperfusion injury in rats Peptides 29 2008 1216
24. G.M. Barton, and R. Medzhitov Toll-like receptor signaling pathways Science 300 2003 1524
25. C. Cook, D. Pisetsky, and D. Schwartz Toll-like receptors in the pathogeneis of human disease Nat Immunol 5 2004 975
26. T. Horng, G.M. Barton, and R. Medzhitov TIRAP: an adapter molecule in the Toll signaling pathway Nat Immunol 2 2001 835
27. T. Horng, G.M. Barton, and R.A. Flavell The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors Nature 420 2002 329
28. K. Hoebe, E.M. Janssen, and S.O. Kim Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways Nat Immunol 4 2003 1223
29. M. Yamamoto, S. Sato, and H. Hemmi TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway Nat Immunol 4 2003 1144
30. W. Jiang, M. Hu, and J. Rao Over-expression of Toll-like receptors and their ligands in small-for-size graft Hepatol Res 40 2010 318
31. A. Arranz, A. Androulidaki, and V. Zacharioudaki Vasoactive intestinal peptide suppresses toll-like receptor 4 expression in macrophages via Akt1 reducing their responsiveness to lipopolysaccharide Mol Immunol 45 2008 2970
32. A. Arranz, C. Abad, and Y. Juarranz Effect of VIP on TLR2 and TLR4 expression in lymph node immune cells during TNBS-induced colitis Ann N Y Acad Sci 1070 2006 129
33. R.P. Gomariz, A. Arranz, and C. Abad Time-course expression of Toll-like receptors 2 and 4 in inflammatory bowel disease and homeostatic effect of VIP J Leukoc Biol 78 2005 491
34. Y. Juarranz, C. Abad, and C. Martinez Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis Arthritis Res Ther 7 2005 R1034
35. W. Ding, J.A. Wagner, and R.D. Granstein CGRP, PACAP, and VIP modulate Langerhans cell function by inhibiting NF-kappaB activation J Invest Dermatol 127 2007 2357
36. H. Natsume, H. Tokuda, and J. Mizutani Synergistic effect of vasoactive intestinal peptides on TNF-alpha-induced IL-6 synthesis in osteoblasts: amplification of p44/p42 MAP kinase activation Int J Mol Med 25 2010 813